Innoviva Operating Margin 2012-2026 | INVA
Current and historical operating margin for Innoviva (INVA) over the last 10 years. The current operating profit margin for Innoviva as of March 31, 2026 is 81.07%.
| Innoviva Operating Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Operating Income | Operating Margin |
| 2026-03-31 | $0.42B | $0.16B | 38.24% |
| 2025-12-31 | $0.41B | $0.16B | 39.81% |
| 2025-09-30 | $0.39B | $0.17B | 43.19% |
| 2025-06-30 | $0.37B | $0.18B | 47.44% |
| 2025-03-31 | $0.37B | $0.18B | 49.06% |
| 2024-12-31 | $0.36B | $0.17B | 46.52% |
| 2024-09-30 | $0.35B | $0.16B | 45.89% |
| 2024-06-30 | $0.33B | $0.14B | 41.52% |
| 2024-03-31 | $0.31B | $0.11B | 35.69% |
| 2023-12-31 | $0.31B | $0.12B | 37.10% |
| 2023-09-30 | $0.29B | $0.10B | 34.83% |
| 2023-06-30 | $0.29B | $0.37B | 128.28% |
| 2023-03-31 | $0.32B | $0.43B | 134.38% |
| 2022-12-31 | $0.33B | $0.47B | 143.20% |
| 2022-09-30 | $0.37B | $0.56B | 148.79% |
| 2022-06-30 | $0.40B | $0.36B | 89.36% |
| 2022-03-31 | $0.40B | $0.38B | 94.46% |
| 2021-12-31 | $0.39B | $0.38B | 95.67% |
| 2021-09-30 | $0.38B | $0.36B | 94.93% |
| 2021-06-30 | $0.37B | $0.35B | 94.26% |
| 2021-03-31 | $0.34B | $0.32B | 94.19% |
| 2020-12-31 | $0.34B | $0.32B | 95.25% |
| 2020-09-30 | $0.32B | $0.31B | 95.98% |
| 2020-06-30 | $0.30B | $0.29B | 95.67% |
| 2020-03-31 | $0.29B | $0.27B | 95.09% |
| 2019-12-31 | $0.26B | $0.25B | 94.64% |
| 2019-09-30 | $0.27B | $0.25B | 94.34% |
| 2019-06-30 | $0.26B | $0.25B | 94.64% |
| 2019-03-31 | $0.26B | $0.25B | 94.70% |
| 2018-12-31 | $0.26B | $0.24B | 91.57% |
| 2018-09-30 | $0.25B | $0.23B | 90.84% |
| 2018-06-30 | $0.24B | $0.21B | 88.24% |
| 2018-03-31 | $0.23B | $0.20B | 84.78% |
| 2017-12-31 | $0.22B | $0.18B | 83.94% |
| 2017-09-30 | $0.19B | $0.16B | 80.73% |
| 2017-06-30 | $0.18B | $0.14B | 81.25% |
| 2017-03-31 | $0.15B | $0.12B | 81.21% |
| 2016-12-31 | $0.13B | $0.11B | 82.71% |
| 2016-09-30 | $0.11B | $0.09B | 79.46% |
| 2016-06-30 | $0.09B | $0.07B | 74.19% |
| 2016-03-31 | $0.07B | $0.05B | 66.67% |
| 2015-12-31 | $0.06B | $0.03B | 56.36% |
| 2015-09-30 | $0.04B | $0.01B | 35.90% |
| 2015-06-30 | $0.03B | $0.00B | -15.38% |
| 2015-03-31 | $0.02B | $-0.02B | -118.75% |
| 2014-12-31 | $0.01B | $-0.04B | -437.50% |
| 2014-09-30 | $0.00B | $-0.02B | -800.00% |
| 2014-06-30 | $0.00B | $-0.01B | -1400.00% |
| 2014-03-31 | $0.00B | $-0.01B | -1100.00% |
| 2013-12-31 | $0.00B | $-0.03B | -966.67% |
| 2013-09-30 | $0.01B | $-0.08B | -975.00% |
| 2013-06-30 | $0.01B | $-0.10B | -1144.44% |
| 2013-03-31 | $0.01B | $-0.13B | -1466.67% |
| 2012-12-31 | $0.14B | $-0.01B | -9.63% |
| 2012-09-30 | $0.13B | $-0.02B | -14.18% |
| 2012-06-30 | $0.14B | $-0.02B | -10.79% |
| 2012-03-31 | $0.14B | $0.00B | -2.08% |
| 2011-12-31 | $0.02B | $-0.11B | -478.26% |
| 2011-09-30 | $0.03B | $-0.09B | -368.00% |
| 2011-06-30 | $0.02B | $-0.08B | -345.83% |
| 2011-03-31 | $0.02B | $-0.08B | -325.00% |
| 2010-12-31 | $0.02B | $-0.08B | -325.00% |
| 2010-09-30 | $0.02B | $-0.08B | -385.71% |
| 2010-06-30 | $0.02B | $-0.08B | -372.73% |
| 2010-03-31 | $0.02B | $-0.08B | -400.00% |
| 2009-12-31 | $0.03B | $-0.08B | -324.00% |
| 2009-09-30 | $0.03B | $-0.08B | -277.78% |
| 2009-06-30 | $0.03B | $-0.08B | -277.78% |
| 2009-03-31 | $0.03B | $-0.08B | -289.29% |
| 2008-12-31 | $0.02B | $-0.09B | -387.50% |
| 2008-09-30 | $0.02B | $-0.11B | -466.67% |
| 2008-06-30 | $0.02B | $-0.13B | -525.00% |
| 2008-03-31 | $0.02B | $-0.15B | -639.13% |
| 2007-12-31 | $0.02B | $-0.17B | -768.18% |
| 2007-09-30 | $0.02B | $-0.18B | -838.10% |
| 2007-06-30 | $0.02B | $-0.18B | -866.67% |
| 2007-03-31 | $0.02B | $-0.18B | -852.38% |
| 2006-12-31 | $0.02B | $-0.18B | -895.00% |
| 2006-09-30 | $0.02B | $-0.18B | -1011.11% |
| 2006-06-30 | $0.02B | $-0.18B | -1200.00% |
| 2006-03-31 | $0.01B | $-0.17B | -1292.31% |
| 2005-12-31 | $0.01B | $-0.15B | -1241.67% |
| 2005-09-30 | $0.01B | $-0.14B | -1133.33% |
| 2005-06-30 | $0.01B | $-0.12B | -1000.00% |
| 2005-03-31 | $0.01B | $-0.12B | -1072.73% |
| 2004-12-31 | $0.01B | $-0.11B | -1177.78% |
| 2004-09-30 | $0.01B | $-0.09B | -1314.29% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $1.760B | $0.411B |
| Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |